4 recruiting, 2 active not recruiting, 1 not yet recruiting, 1 terminated. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Active not recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy JS207 injection +docetaxel, JS207 injection +JS004 injection, JS207 injection - Advanced NSCLC | Phase 2 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 18 | 2025-07-15 | 2026-09-25 |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Cabozantinib, Atezolizumab - Lung Cancer, NSCLC Stage IV | Phase 2 | Not yet recruiting | Jun Zhang, MD, PhD | 40 | 2024-12-01 | 2024-05-08 |
| Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment Radiotherapy, PD-1 inhibitor, Neoantigen-loaded DC vaccine - Advanced NSCLC | Phase 2 | Recruiting | The First Affiliated Hospital of Nanchang University | 10 | 2024-03-11 | 2024-12-30 |
| Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment Radiotherapy, PD-1 inhibitor, Neoantigen-based peptide vaccine - Advanced NSCLC | Phase 2 | Recruiting | The First Affiliated Hospital of Nanchang University | 10 | 2024-03-11 | 2024-12-30 |
| A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor HB0025, Pemetrexed, Paclitaxel - Advanced NSCLC, Advanced Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Huabo Biopharm Co., Ltd. | 282 | 2024-01-31 | 2025-01-23 |
| Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations CT053PTSA - Advanced NSCLC | Phase 2 | Withdrawn | Sunshine Lake Pharma Co., Ltd. | 2022-11-27 | 2026-05-14 | |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed - Advanced NSCLC, Metastatic Lung Cancer | Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 90 | 2022-11-22 | 2026-06-23 |
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Nivolumab, Oxaliplatin, Ipilimumab - Advanced NSCLC | Phase 1 / Phase 2 | Active not recruiting | Hatim Husain | 30 | 2019-08-14 | 2025-05-28 |
| Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Thalidomide, pemetrexed, cisplatin - Advanced Nsclc | Phase 2 | Unknown | Qilu Hospital of Shandong University | 232 | 2016-12-01 | 2019-06-05 |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Aldesleukin, Fludarabine, Cyclophosphamide - Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 85 | 2014-10-23 | 2026-10-20 |
Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (3) · Adenocarcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (5) · Neoplasms by Site (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Lung Neoplasms (1)
Carboplatin (3) · Cisplatin (2) · Immune Checkpoint Inhibitors (2) · Pemetrexed (2) · Radiotherapy (2) · Cyclophosphamide (1) · Ipilimumab (1) · Nivolumab (1) · Oxaliplatin (1) · Paclitaxel (1) · Thalidomide (1) · aldesleukin (1) · atezolizumab (1) · cabozantinib (1) · fludarabine (1)
The First Affiliated Hospital of Nanchang University (2) · Hatim Husain (1) · Huabo Biopharm Co., Ltd. (1) · Jun Zhang, MD, PhD (1) · Mirati Therapeutics Inc. (1) · National Cancer Institute (NCI) (1) · Qilu Hospital of Shandong University (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Sunshine Lake Pharma Co., Ltd. (1)
China (5) · United States (4) · France (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1)
Caicun Zhou, PhD. (1) · Hatim Husain (1) · James C Yang, M.D. (1) · Jun Zhang, MD, PhD (1) · Jundong Li, PhD. (1) · Li Zhang, MD (1) · Xiuwen Wang, MD.PhD (1)